The IL-12 family of heterodimeric cytokines in polycystic ovarian syndrome: biological role in induction, regulation, and treatment
- PMID: 38771486
- DOI: 10.1007/s12026-024-09487-4
The IL-12 family of heterodimeric cytokines in polycystic ovarian syndrome: biological role in induction, regulation, and treatment
Abstract
Polycystic ovary syndrome (PCOS) is a diverse endocrine disorder widely recognized as the prevailing metabolic condition among women in their reproductive years. The precise pathophysiological mechanisms underlying PCOS remain incompletely understood. However, existing evidence suggests that the development of PCOS may be linked to factors such as abdominal obesity, hyperandrogenism, and insulin resistance (IR). Excessive central adiposity in women with PCOS may lead to the development of a chronic, low-grade inflammation characterized by the activation of proinflammatory cytokines. The cytokines that belong to the IL-12 family are a collection of distinct heterodimeric cytokines that include IL-12, IL-23, IL-27, and IL-35. Recent research has provided further evidence regarding the significance of IL-12 cytokines in influencing both innate and adaptive immune responses in different diseases. Additionally, these studies have discovered diverse roles for certain members of the IL-12 family, encompassing multiple immunological functions that can either act as effectors or regulators. In this discourse, we examine the distinctive and atypical structural and functional attributes of this particular cytokine family. This study aims to offer a comprehensive overview of the pathophysiological significance of the IL-12 family cytokines in PCOS patients. Additionally, the therapeutic potential of the cytokines as novel approaches for PCOS treatment will be proposed.
Keywords: Cytokine; IL-12 family; PCOS; Polycystic ovary syndrome.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Chronic Low Grade Inflammation in Pathogenesis of PCOS.Int J Mol Sci. 2021 Apr 6;22(7):3789. doi: 10.3390/ijms22073789. Int J Mol Sci. 2021. PMID: 33917519 Free PMC article. Review.
-
Systemic and ovarian inflammation in women with polycystic ovary syndrome.J Reprod Immunol. 2022 Jun;151:103628. doi: 10.1016/j.jri.2022.103628. Epub 2022 Apr 16. J Reprod Immunol. 2022. PMID: 35472833
-
Opportunities and challenges: interleukin-22 comprehensively regulates polycystic ovary syndrome from metabolic and immune aspects.J Ovarian Res. 2023 Jul 31;16(1):149. doi: 10.1186/s13048-023-01236-9. J Ovarian Res. 2023. PMID: 37525285 Free PMC article. Review.
-
Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study.J Ovarian Res. 2024 May 11;17(1):100. doi: 10.1186/s13048-024-01428-x. J Ovarian Res. 2024. PMID: 38734641 Free PMC article.
-
Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.Arch Gynecol Obstet. 2021 Mar;303(3):631-643. doi: 10.1007/s00404-020-05951-2. Epub 2021 Jan 13. Arch Gynecol Obstet. 2021. PMID: 33439300
Cited by
-
In-depth plasma N-glycoproteome profiling using narrow-window data-independent acquisition on the Orbitrap Astral mass spectrometer.Nat Commun. 2025 Mar 13;16(1):2497. doi: 10.1038/s41467-025-57916-1. Nat Commun. 2025. PMID: 40082474 Free PMC article.
References
-
- Deans R. Polycystic ovary syndrome in adolescence. Med Sci. 2019;7(10):101.
-
- Su Y-N, Wang M-J, Yang J-P, Wu X-L, Xia M, Bao M-H, et al. Effects of Yulin Tong Bu formula on modulating gut microbiota and fecal metabolite interactions in mice with polycystic ovary syndrome. Front Endocrinol. 2023;14:1122709. - DOI
-
- Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: what’s new? Adv Clin Exp Med. 2017;26(2):59–367. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical